Latest Breaking News On - Database consortium - Page 3 : comparemela.com

XORTX Therapeutics Inc (XRTX) Appoints Ronald Perrone to its Board

XORTX Therapeutics Inc (XRTX) Appoints Ronald Perrone to its Board
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesBoston university medical centerRon perroneRichard johnsonCharles edelsteinAllen davidoffPetter bjornstadFederico maeseRonald perroneAnjay rostogiPalladio biosciencesEuropean medicines agencyDrug administrationXortx therapeutics incNational institute of healthCritical path institute

XORTX Announces New Clinical Advisory Board Member

XORTX Announces New Clinical Advisory Board Member
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesBoston university medical centerAnjay rostogiPalladio biosciencesKim golodetzFederico maeseRonald perroneCharles edelsteinAllen davidoffNick rigopulosPetter bjornstadRichard johnsonRon perroneTherapeutics incDrug administrationEuropean medicines agency

Network Meta-Analysis Sheds Light on Efficacy of Lenvatinib Plus Pembrolizumab Vs SOC in Advanced RCC

Lenvatinib/pembrolizumab shows a trend of improved PFS and overall response rate vs standard immunotherapies in advanced renal cell carcinoma.

Lenvatinib lenvimaInternational metastaticDatabase consortiumLenvatinib pembrolizumabAdvanced renal cell carcinoma

Bristol-Myers Squibb (BMY) Reports Eight-Year Data for Opdivo Plus Yervoy Continued to Demonstrate Longest Survival Benefit vs Sunitinib

Bristol-Myers Squibb (BMY) Reports Eight-Year Data for Opdivo Plus Yervoy Continued to Demonstrate Longest Survival Benefit vs Sunitinib
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNizar tannirBristol myers squibbDana walkerDepartment of genitourinary medical oncologyDatabase consortiumDivision of cancer medicineAmerican society of clinical oncologyInternational metastaticUniversity of texasMd anderson cancer centerAmerican societyClinical oncologyCancers symposiumHazard ratioConfidence interval

Bristol Myers Squibb - Eight-Year Data for Opdivo Plus Yervoy Continue to Demonstrate Longest Survival Benefit vs Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

PRINCETON - Bristol Myers Squibb today announced that Opdivo plus Yervoy continued to demonstrate long-term survival results in the Phase 3 CheckMate -214 trial, reducing the risk of death by 28%.

United statesSouth koreaNizar tannirDana walkerBristol myers squibbDrug administrationDivision of cancer medicineCompany opdivoEuropean unionUniversity of texasInternational metastaticMd anderson cancer centerExchange commissionDepartment of genitourinary medical oncologyAmerican society of clinical oncologyDatabase consortium